First Tracks Biotherapeutics Inc (NASDAQ: TRAX) is a Healthcare company (Biotechnology) with a market capitalization of $1.8B. The Maz Rating grades it against the other companies in its sector.
First Tracks Biotherapeutics Inc's current Maz Rating and its five factor grades are for members: log in to see them.
At $43.36, First Tracks Biotherapeutics Inc trades at 11.0x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -72.9%, return on invested capital of -107.6% and a free cash flow yield of -6.1%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 9.16. Over the past 52 weeks the share price ranged from $14.72 to $54.78, with a beta of 3.37.
First Tracks Biotherapeutics Inc does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 10 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, First Tracks Biotherapeutics Inc (TRAX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.26% / 30% · (Cash+Inv) / Mkt Cap (36m) 10.8% / 30% · Interest income / Revenue 149500000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.26% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 10.8% / 33% · Receivables / Mkt Cap (36m) 0.20% / 49% · Interest income / Revenue 149500000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.26% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 10.8% / 33.33% · Receivables / Mkt Cap (24m) 0.20% / 33.33% · Interest income / Revenue 149500000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 2.08% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 94.6% / 33.33% · Receivables / Avg Assets (4Q) 0.29% / 33.33% · Interest income / Revenue 149500000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 2.21% / 33.33% · (Cash+ST Inv) / Total Assets 91.3% / 33.33% · (Cash+Recv) / Total Assets 93.0% / 33.33% · Interest income / Revenue 149500000.0% / 5% | Fail |
No. As of September 2026, First Tracks Biotherapeutics Inc (TRAX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. First Tracks Biotherapeutics Inc is over the AAOIFI limit on Interest income / Revenue.
About 149500000.0% of each dividend: First Tracks Biotherapeutics Inc's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.